Last reviewed · How we verify
Liposomal Bupivacaine 10mL
At a glance
| Generic name | Liposomal Bupivacaine 10mL |
|---|---|
| Sponsor | Zhejiang University |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
- Nausea and vomiting
- Postoperative neurologic symptoms at 7 days after surgery
- Bruising
- Rash
- Swelling
- Inflammation
- Ringing in ears
- Numbness and tingling
- Postoperative neurologic symptoms at 14 days after surgery
Key clinical trials
- Liposomal Bupivacaine With Standard Bupivacaine Versus Dexmedetomidine With Standard Bupivacaine (PHASE3)
- Perioperative Multimodal Analgesia for Supratentorial Craniotomy (NA)
- Laparoscopic Transversus Abdominis Plane (TAP) Block to Reduce Post-operative Opioids (PHASE2, PHASE3)
- Autonomic Neural Blockade in Bariatric Surgery (NA)
- Evaluation of Diaphragmatic Function After Interscalene Block With Liposomal Bupivacaine (NA)
- Combination Versus Alone Liposomal Bupivacaine Blocks in Minimally Invasive Thoracic Surgery-1 (NA)
- Analgesic Efficacy of Different Liposomal Bupivacaine Doses in the Adductor Canal Block for Total Knee Arthroplasty (PHASE3)
- Utility of Liposomal Bupivacaine Transversus Abdominal Plane Block for Open Myomectomy (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Liposomal Bupivacaine 10mL CI brief — competitive landscape report
- Liposomal Bupivacaine 10mL updates RSS · CI watch RSS
- Zhejiang University portfolio CI